Back to results
US 2025/0052770 A1Published application
Glx-derived molecule detection
AssigneeGLX Analytix ApS
InventorsBrian William Della Valle, Casper Hempel
Life of this patent
Estimating the term…
Abstract
The present invention relates to biomarkers associated with immune-mediated inflammatory disease (IMID), particular GLX molecules, and even more particular GLX-related glycosaminglycans (GAGs) and GLX-related proteoglycans (PGs).
Claims2
An ex vivo method of diagnosing and/or prognosticating at least one immune-mediated inflammatory disease (IMID) in a subject, said method comprising:
- a. performing an in vitro measurement of the level of one or more biomarkers selected from the group consisting of glycosaminoglycans (GAGs) and proteoglycans (PGs) of the glycocalyx in a first biological sample from the subject;
- b. optionally, performing an in vitro measurement of the level of the one or more biomarkers in a second or additional biological samples from the subject obtained at a later time point than said first biological sample;
- c. comparing the level of said one or more biomarkers to the level of one or more corresponding references;
- and
- d. using the measured value to evaluate the IMID state of the subject.
2 more elements
2-28. (canceled)
Dependencies are inferred from the claim text.